Etrasimod is under clinical development by Pfizer and currently in Phase II for Eosinophilic Esophagitis. According to GlobalData, Phase II drugs for Eosinophilic Esophagitis have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Etrasimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Etrasimod overview

Etrasimod (Velsipity) is an immunomodulatory agent. It is formulated as film coated tablets for oral route of administration. Velsipity is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Etrasimod (APD-334) is under development for the treatment of moderately to severely active ulcerative colitis, Crohn's disease, atopic dermatitis, alopecia areta and Eosinophilic Esophagitis (EOE). The drug candidate is a next-generation small molecule and is administered through oral route. It acts by targeting S1P1, S1P4 and S1P5 receptors. It is developed based on GPCR-based drug discovery technology platform. It was also under development for autoimmune diseases such as multiple sclerosis, psoriasis, rheumatoid arthritis and dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease. It was also under development for pyoderma gangrenosum and primary biliary cirrhosis (cholangitis).

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Etrasimod’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.